Matrix metalloproteinases: Protective roles in cancer

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 6, 2011, Pages 1254-1265

  Decock, Julie ^a   Thirkettle, Sally ^a   Wagstaff, Laura ^b   Edwards, Dylan R ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Anti target; Cancer; Matrix metalloproteinases; Protective

Indexed keywords

ENZYME INHIBITOR; MATRIX METALLOPROTEINASE;

ANIMAL; ARTICLE; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MOUSE; MOUSE MUTANT; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); VASCULARIZATION;

ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, KNOCKOUT; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 79957651592     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01302.x     Document Type: Article

References (108)

1. World Health Organization. World Cancer Report 2008. Lyon: World Health Organization; 2008.
2. Danaei G, Vander HS, Lopez AD, et al Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005; 366: 1784-93.
3. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002; 115: 3719-27.
4. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med. 2008; 29: 258-89.
5. Kruger A, Kates RE, Edwards DR. Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochim Biophys Acta. 2010; 1803: 95-102.
6. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002; 295: 2387-92.
7. Fingleton B. MMP Inhibitor Clinical Trials - the past, present, and future. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF, editors. The cancer degradome - proteases and cancer biology. New York: Springer; 2011. pp. 759-86.
8. Bramhall SR, Hallissey MT, Whiting J, et al Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer. 2002; 86: 1864-70.
9. Bergers G, Javaherian K, Lo KM, et al Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 1999; 284: 808-12.
10. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2: 161-74.
11. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer. 2007; 7: 800-8.
12. Martin MD, Matrisian LM. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev. 2007; 26: 717-24.
13. Lopez-Otin C, Palavalli LH, Samuels Y. Protective roles of matrix metalloproteinases: from mouse models to human cancer. Cell Cycle. 2009; 8: 3657-62.
14. Devy L, Huang L, Naa L, et al Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 2009; 69: 1517-26.
15. Suojanen J, Salo T, Koivunen E, et al A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth. Cancer Biol Ther. 2009; 8: 2362-70.
16. Overall CM, Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer. 2006; 94: 941-6.
17. Blavier L, Lazaryev A, Dorey F, et al Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis. Cancer Res. 2006; 66: 2691-9.
18. Pedersen TX, Pennington CJ, Almholt K, et al Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas. Carcinogenesis. 2005; 26: 1233-40.
19. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006; 69: 562-73.
20. McCawley LJ, Crawford HC, King LE Jr, et al A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res. 2004; 64: 6965-72.
21. McCawley LJ, Wright J, LaFleur BJ, et al Keratinocyte expression of MMP3 enhances differentiation and prevents tumor establishment. Am J Pathol. 2008; 173: 1528-39.
22. Witty JP, Lempka T, Coffey RJ Jr, et al Decreased tumor formation in 7, 12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis. Cancer Res. 1995; 55: 1401-6.
23. Sternlicht MD, Lochter A, Sympson CJ, et al The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell. 1999; 98: 137-46.
24. Sun T, Gao Y, Tan W, et al Haplotypes in matrix metalloproteinase gene cluster on chromosome 11q22 contribute to the risk of lung cancer development and progression. Clin Cancer Res. 2006; 12: 7009-17.
25. Zinzindohoue F, Blons H, Hans S, et al Single nucleotide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head and neck squamous cell carcinoma. Anticancer Res. 2004; 24: 2021-6.
26. Fang S, Jin X, Wang R, et al Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis. 2005; 26: 481-6.
27. Krippl P, Langsenlehner U, Renner W, et al The 5A/6A polymorphism of the matrix metalloproteinase 3 gene promoter and breast cancer. Clin Cancer Res. 2004; 10: 3518-20.
28. Zhang J, Jin X, Fang S, et al The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma. Carcinogenesis. 2004; 25: 2519-24.
29. Ghilardi G, Biondi ML, Caputo M, et al A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res. 2002; 8: 3820-3.
30. Medley TL, Kingwell BA, Gatzka CD, et al Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res. 2003; 92: 1254-61.
31. Ye S, Eriksson P, Hamsten A, et al Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 1996; 271: 13055-60.
32. Van Lint P, Libert C. Matrix metalloproteinase-8: cleavage can be decisive. Cytokine Growth Factor Rev. 2006; 17: 217-23.
33. Gutierrez-Fernandez A, Fueyo A, Folgueras AR, et al Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res. 2008; 68: 2755-63.
34. Balbin M, Fueyo A, Tester AM, et al Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet. 2003; 35: 252-7.
35. Agarwal D, Goodison S, Nicholson B, et al Expression of matrix metalloproteinase 8 (MMP-8) and tyrosinase-related protein-1 (TYRP-1) correlates with the absence of metastasis in an isogenic human breast cancer model. Differentiation. 2003; 71: 114-25.
36. Montel V, Kleeman J, Agarwal D, et al Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression. Cancer Res. 2004; 64: 1687-94.
37. Palavalli LH, Prickett TD, Wunderlich JR, et al Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet. 2009; 41: 518-20.
38. Korpi JT, Kervinen V, Maklin H, et al Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. Br J Cancer. 2008; 98: 766-75.
39. Decock J, Hendrickx W, Vanleeuw U, et al Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis. BMC Cancer. 2008; 8: 77-84.
40. Decock J, Long JR, Laxton RC, et al Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis. Cancer Res. 2007; 67: 10214-21.
41. Gonzalez-Arriaga P, Lopez-Cima MF, Fernandez-Somoano A, et al Polymorphism +17 C/G in matrix metalloprotease MMP8 decreases lung cancer risk. BMC Cancer. 2008; 8: 378.
42. Wang H, Parry S, Macones G, et al Functionally significant SNP MMP8 promoter haplotypes and preterm premature rupture of membranes (PPROM). Hum Mol Genet. 2004; 13: 2659-69.
43. Tester AM, Cox JH, Connor AR, et al LPS responsiveness and neutrophil chemotaxis In vivo require PMN MMP-8 activity. PLoS One. 2007; 2: e312.
44. Gutierrez-Fernandez A, Inada M, Balbin M, et al Increased inflammation delays wound healing in mice deficient in collagenase-2 (MMP-8). FASEB J. 2007; 21: 2580-91.
45. Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta. 2004; 1705: 69-89.
46. Bergers G, Brekken R, McMahon G, et al Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000; 2: 737-44.
47. Chantrain CF, Shimada H, Jodele S, et al Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 2004; 64: 1675-86.
48. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009; 27: 5287-97.
49. Li HC, Cao DC, Liu Y, et al Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat. 2004; 88: 75-85.
50. Pellikainen JM, Ropponen KM, Kataja VV, et al Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res. 2004; 10: 7621-8.
51. Vizoso FJ, Gonzalez LO, Corte MD, et al Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer. 2007; 96: 903-11.
52. Scorilas A, Karameris A, Arnogiannaki N, et al Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Br J Cancer. 2001; 84: 1488-96.
53. Coussens LM, Tinkle CL, Hanahan D, et al MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000; 103: 481-90.
54. Bendrik C, Robertson J, Gauldie J, et al Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer In vivo. Cancer Res. 2008; 68: 3405-12.
55. Hamano Y, Zeisberg M, Sugimoto H, et al Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell. 2003; 3: 589-601.
56. Kerkela E, Bohling T, Herva R, et al Human macrophage metalloelastase (MMP-12) expression is induced in chondrocytes during fetal development and malignant transformation. Bone. 2001; 29: 487-93.
57. Shapiro SD, Kobayashi DK, Ley TJ. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem. 1993; 268: 23824-9.
58. Hou P, Troen T, Ovejero MC, et al Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption. Bone. 2004; 34: 37-47.
59. Hofmann HS, Hansen G, Richter G, et al Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients. Clin Cancer Res. 2005; 11: 1086-92.
60. Kerkela E, la-aho R, Jeskanen L, et al Expression of human macrophage metalloelastase (MMP-12) by tumor cells in skin cancer. J Invest Dermatol. 2000; 114: 1113-9.
61. Kerkela E, la-aho R, Klemi P, et al Metalloelastase (MMP-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome. J Pathol. 2002; 198: 258-69.
62. Gorrin-Rivas MJ, Arii S, Furutani M, et al Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. Clin Cancer Res. 2000; 6: 1647-54.
63. Gorrin-Rivas MJ, Arii S, Mori A, et al Implications of human macrophage metalloelastase and vascular endothelial growth factor gene expression in angiogenesis of hepatocellular carcinoma. Ann Surg. 2000; 231: 67-73.
64. Gorrin Rivas MJ, Arii S, Furutani M, et al Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: correlation with angiostatin generation and its clinical significance. Hepatology. 1998; 28: 986-93.
65. Shi H, Xu JM, Hu NZ, et al Transfection of mouse macrophage metalloelastase gene into murine CT-26 colon cancer cells suppresses orthotopic tumor growth, angiogenesis and vascular endothelial growth factor expression. Cancer Lett. 2006; 233: 139-50.
66. Xu Z, Shi H, Li Q, et al Mouse macrophage metalloelastase generates angiostatin from plasminogen and suppresses tumor angiogenesis in murine colon cancer. Oncol Rep. 2008; 20: 81-8.
67. Gorrin-Rivas MJ, Arii S, Mori A, et al Mouse macrophage metalloelastase gene delivery by HVJ-cationic liposomes in experimental antiangiogenic gene therapy for murine CT-26 colon cancer. Int J Cancer. 2001; 93: 731-5.
68. Zhang H, Li Y, Xu G. Human macrophage metalloelastase expression in gastric cancer and its relationship with gastric cancer prognosis. J Exp Clin Cancer Res. 2007; 26: 361-6.
69. Asano T, Tada M, Cheng S, et al Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma. J Surg Res. 2008; 146: 32-42.
70. Yang W, Arii S, Gorrin-Rivas MJ, et al Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. Cancer. 2001; 91: 1277-83.
71. Acuff HB, Sinnamon M, Fingleton B, et al Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. Cancer Res. 2006; 66: 7968-75.
72. Houghton AM, Grisolano JL, Baumann ML, et al Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res. 2006; 66: 6149-55.
73. Margheri F, Serrati S, Lapucci A, et al Systemic sclerosis-endothelial cell antiangiogenic pentraxin 3 and matrix metalloprotease 12 control human breast cancer tumor vascularization and development in mice. Neoplasia. 2009; 11: 1106-15.
74. Jormsjo S, Ye S, Moritz J, et al Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res. 2000; 86: 998-1003.
75. Scherf DB, Dally H, Muller P, et al Single nucleotide polymorphisms in matrix metalloproteinase genes and lung cancer chemotherapy response and prognosis. Eur Respir J. 2010; 35: 381-90.
76. Dean RA, Cox JH, Bellac CL, et al Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx. Blood. 2008; 112: 3455-64.
77. Mueller MS, Mauch S, Sedlacek R. Structure of the human MMP-19 gene. Gene. 2000; 252: 27-37.
78. Pendas AM, Knauper V, Puente XS, et al Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem. 1997; 272: 4281-6.
79. Yang M, Kurkinen M. Cloning and characterization of a novel matrix metalloproteinase (MMP), CMMP, from chicken embryo fibroblasts. CMMP, Xenopus XMMP, and human MMP19 have a conserved unique cysteine in the catalytic domain. J Biol Chem. 1998; 273: 17893-900.
80. Stracke JO, Fosang AJ, Last K, et al Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP). FEBS Lett. 2000; 478: 52-6.
81. Stracke JO, Hutton M, Stewart M, et al Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme. J Biol Chem. 2000; 275: 14809-16.
82. Kolb C, Mauch S, Krawinkel U, et al Matrix metalloproteinase-19 in capillary endothelial cells: expression in acutely, but not in chronically, inflamed synovium. Exp Cell Res. 1999; 250: 122-30.
83. Bister VO, Salmela MT, Karjalainen-Lindsberg ML, et al Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer. Dig Dis Sci. 2004; 49: 653-61.
84. Djonov V, Hogger K, Sedlacek R, et al MMP-19: cellular localization of a novel metalloproteinase within normal breast tissue and mammary gland tumours. J Pathol. 2001; 195: 147-55.
85. Impola U, Toriseva M, Suomela S, et al Matrix metalloproteinase-19 is expressed by proliferating epithelium but disappears with neoplastic dedifferentiation. Int J Cancer. 2003; 103: 709-16.
86. Impola U, Uitto VJ, Hietanen J, et al Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer. J Pathol. 2004; 202: 14-22.
87. Impola U, Jeskanen L, Ravanti L, et al Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds. Br J Dermatol. 2005; 152: 720-6.
88. Jost M, Folgueras AR, Frerart F, et al Earlier onset of tumoral angiogenesis in matrix metalloproteinase-19-deficient mice. Cancer Res. 2006; 66: 5234-41.
89. Titz B, Dietrich S, Sadowski T, et al Activity of MMP-19 inhibits capillary-like formation due to processing of nidogen-1. Cell Mol Life Sci. 2004; 61: 1826-33.
90. Puente XS, Gutierrez-Fernandez A, Ordonez GR, et al Comparative genomic analysis of human and chimpanzee proteases. Genomics. 2005; 86: 638-47.
91. Ahokas K, Skoog T, Suomela S, et al Matrilysin-2 (matrix metalloproteinase-26) is upregulated in keratinocytes during wound repair and early skin carcinogenesis. J Invest Dermatol. 2005; 124: 849-56.
92. Lee S, Desai KK, Iczkowski KA, et al Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor. Cell Res. 2006; 16: 750-8.
93. Savinov AY, Remacle AG, Golubkov VS, et al Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients. Cancer Res. 2006; 66: 2716-24.
94. Zhao YG, Xiao AZ, Park HI, et al Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: a putative role in the initiation of breast cancer invasion. Cancer Res. 2004; 64: 590-8.
95. Isaka K, Nishi H, Nakai H, et al Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma. Cancer. 2003; 97: 79-89.
96. Pilka R, Norata GD, Domanski H, et al Matrix metalloproteinase-26 (matrilysin-2) expression is high in endometrial hyperplasia and decreases with loss of histological differentiation in endometrial cancer. Gynecol Oncol. 2004; 94: 661-70.
97. Stokes A, Joutsa J, Ala-aho R, et al Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma. Clin Cancer Res. 2010; 16: 2022-35.
98. Riddick AC, Shukla CJ, Pennington CJ, et al Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer. 2005; 92: 2171-80.
99. Park HI, Ni J, Gerkema FE, et al Identification and characterization of human endometase (Matrix metalloproteinase-26) from endometrial tumor. J Biol Chem. 2000; 275: 20540-4.
100. Pilka R, Whatling C, Domanski H, et al Epithelial expression of matrix metalloproteinase-26 is elevated at mid-cycle in the human endometrium. Mol Hum Reprod. 2003; 9: 271-7.
101. Li W, Savinov AY, Rozanov DV, et al Matrix metalloproteinase-26 is associated with estrogen-dependent malignancies and targets alpha1-antitrypsin serpin. Cancer Res. 2004; 64: 8657-65.
102. Holten-Andersen MN, Stephens RW, Nielsen HJ, et al High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res. 2000; 6: 4292-9.
103. Frederiksen C, Lomholt AF, Davis GJ, et al Changes in plasma TIMP-1 levels after resection for primary colorectal cancer. Anticancer Res. 2009; 29: 75-81.
104. Frederiksen C, Lykke J, Christensen IJ, et al Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer. Scand J Clin Lab Invest. 2007; 67: 545-52.
105. Frederiksen C, Qvortrup C, Christensen IJ, et al Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer. Ann Oncol. 2011; 22: 369-75.
106. Atkinson JM, Falconer RA, Edwards DR, et al Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases. Cancer Res. 2010; 70: 6902-12.
107. Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006; 6: 227-39.
108. Edwards D, Hoyer-Hansen G, Blasi F, et al The cancer degradome - proteases and cancer biology. New York: Springer; 2009.